Jacques Grosset

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. doi request reprint Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207)
    Jacques H Grosset
    Center for Tuberculosis Research, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB2 Suite 103, Baltimore, MD, USA
    Expert Rev Anti Infect Ther 11:649-51. 2013
  2. pmc Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice
    Jacques H Grosset
    Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Am J Respir Crit Care Med 188:608-12. 2013
  3. pmc Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide
    Jacques Grosset
    Center for Tuberculosis Research, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 109:15001-5. 2012
  4. pmc In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis
    Deepak Almeida
    Center for Tuberculosis Research, 1550 Orleans Street, Room 105, Baltimore, MD 21231, USA
    Antimicrob Agents Chemother 51:4261-6. 2007
  5. pmc Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis
    Deepak Almeida
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Antimicrob Agents Chemother 53:4178-84. 2009
  6. pmc Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis
    Rokeya Tasneen
    Center for Tuberculosis Research, Johns Hopkins University, 1550 Orleans Street, Baltimore, MD 21231 1002, USA
    Antimicrob Agents Chemother 52:3664-8. 2008
  7. ncbi request reprint Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice
    Sanjay K Jain
    Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Infect Dis 195:1634-42. 2007
  8. doi request reprint Murine model to study the invasion and survival of Mycobacterium tuberculosis in the central nervous system
    Nicholas A Be
    Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 198:1520-8. 2008
  9. pmc Methionine aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targets
    Omonike Olaleye
    Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    Chem Biol 17:86-97. 2010
  10. pmc Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice
    Petros C Karakousis
    Dept of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, 1503 E Jefferson St, Rm 112, Baltimore, MD 21231, USA
    J Exp Med 200:647-57. 2004

Collaborators

Detail Information

Publications14

  1. doi request reprint Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207)
    Jacques H Grosset
    Center for Tuberculosis Research, Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB2 Suite 103, Baltimore, MD, USA
    Expert Rev Anti Infect Ther 11:649-51. 2013
    ..The loading doses partially overcame the delayed antimicrobial activity only in patients treated daily with as much as 400 mg. ..
  2. pmc Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice
    Jacques H Grosset
    Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Am J Respir Crit Care Med 188:608-12. 2013
    ..Although observational studies suggest that clofazimine-containing regimens are highly active against drug-resistant tuberculosis, the contribution of clofazimine for the treatment of this disease has never been systematically evaluated...
  3. pmc Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide
    Jacques Grosset
    Center for Tuberculosis Research, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 109:15001-5. 2012
    ..Our data show that a mouse model can be used to analyze the EBA of TB drugs, and our findings support pursuing clinical trials to evaluate the possible benefit of removing isoniazid after the first 2 treatment days...
  4. pmc In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis
    Deepak Almeida
    Center for Tuberculosis Research, 1550 Orleans Street, Room 105, Baltimore, MD 21231, USA
    Antimicrob Agents Chemother 51:4261-6. 2007
    ..Although this target cannot be achieved clinically with MXF, it might be possible with new fluoroquinolones with more potent activity and/or improved pharmacokinetics...
  5. pmc Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis
    Deepak Almeida
    Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Antimicrob Agents Chemother 53:4178-84. 2009
    ..Finally, a 10-mg/kg dose of INH in mice may best represent the 5-mg/kg dose in humans and decrease the antagonism of INH with RIF-PZA...
  6. pmc Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis
    Rokeya Tasneen
    Center for Tuberculosis Research, Johns Hopkins University, 1550 Orleans Street, Baltimore, MD 21231 1002, USA
    Antimicrob Agents Chemother 52:3664-8. 2008
    ....
  7. ncbi request reprint Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice
    Sanjay K Jain
    Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Infect Dis 195:1634-42. 2007
    ..However, unlike mice, M. tuberculosis-infected guinea pigs form caseating granulomas, which may simulate human disease more closely...
  8. doi request reprint Murine model to study the invasion and survival of Mycobacterium tuberculosis in the central nervous system
    Nicholas A Be
    Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 198:1520-8. 2008
    ..It develops after hematogenous dissemination and subsequent invasion of the CNS by Mycobacterium tuberculosis. The microbial determinants involved in CNS disease are poorly characterized...
  9. pmc Methionine aminopeptidases from Mycobacterium tuberculosis as novel antimycobacterial targets
    Omonike Olaleye
    Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    Chem Biol 17:86-97. 2010
    ..Moreover, knockdown of MtMetAP1a, but not MtMetAP1c, resulted in decreased viability of M. tuberculosis. These results suggest that MtMetAP1a is a promising target for developing antituberculosis agents...
  10. pmc Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice
    Petros C Karakousis
    Dept of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, 1503 E Jefferson St, Rm 112, Baltimore, MD 21231, USA
    J Exp Med 200:647-57. 2004
    ..Interestingly, the dormancy phenotype of extracellular M. tuberculosis within host granulomas appears to be immune mediated and interferon-gamma dependent...
  11. pmc Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis
    Tetsuyuki Yoshimatsu
    Division of Infectious Diseases, Department of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1001, USA
    Antimicrob Agents Chemother 46:1875-9. 2002
    ..e., once-weekly) therapy and should be evaluated in the mouse model of TB...
  12. pmc Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary
    Jacques Grosset
    Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1001, USA
    Antimicrob Agents Chemother 47:833-6. 2003
  13. pmc A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis
    Gyanu Lamichhane
    Center for Tuberculosis Research, Department of Medicine, The Johns Hopkins University School of Medicine, 424 North Bond Street, Baltimore, MD 21231 1001, USA
    Proc Natl Acad Sci U S A 100:7213-8. 2003
    ..At subsaturation levels of mutagenesis with a random transposon such as Himar1, this approach permits a statistical prediction of both the proportion and identities of essential genes of sequenced genomes...
  14. pmc Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice
    Ming Zhang
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1501 Orleans Street, Baltimore, MD 21231, USA
    Am J Respir Crit Care Med 183:1254-61. 2011
    ..Daily rifapentine plus isoniazid-pyrazinamide in mice infected with Mycobacterium tuberculosis produces cure in 3 months. Whether cure corresponds to latent infection contained by host immunity or true tissue sterilization is unknown...

Research Grants2

  1. Firing up new treatments against Mycobacterium ulcerans disease (Buruli ulcer)
    Jacques H Grosset; Fiscal Year: 2010
    ..Previous work has already succeeded in identifying treatment regimens that can replace or reduce surgery and skin grafting whereas we now seek to identify completely oral treatments to replace injected antibiotics. ..